Table 2.
Prognostic factors for intracranial failure.
| Variables | Univariate analysis | Multivariate analysis | |||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI for HR | p | HR | 95% CI for HR | p | ||||
| Lower | Upper | Lower | Upper | ||||||
| Age (years) | ≥ 65 (vs. < 65) | 0.46 | 0.19 | 1.14 | 0.095 | 0.6 | 0.19 | 1.92 | 0.391 |
| Sex | F (vs. M) | 2.4 | 0.88 | 6.58 | 0.088 | 1.68 | 0.47 | 6.01 | 0.424 |
| T stage | T3, 4 (vs. T1, 2) | 1.12 | 0.49 | 2.75 | 0.737 | 1.9 | 0.61 | 5.92 | 0.271 |
| N stage | N3 (vs. N0-2) | 1.66 | 0.64 | 4.33 | 0.298 | 1.99 | 0.54 | 7.28 | 0.301 |
| Chemotherapy cycles | 6 (vs. 4) | 0.78 | 0.3 | 2.03 | 0.61 | 0.86 | 0.26 | 2.8 | 0.803 |
| Initial treatment response | PR/SD (vs. CR) | 0.77 | 0.23 | 2.65 | 0.681 | 1.4 | 0.16 | 12.2 | 0.761 |
| Interval, diagnosis to PCI (mo) | > 3 (vs. ≤ 3 ) | 0.91 | 0.38 | 2.16 | 0.827 | 1.71 | 0.59 | 4.97 | 0.325 |
| Locoregional failure | Yes (vs. No) | 1.03 | 0.44 | 2.44 | 0.939 | 0.81 | 0.29 | 2.31 | 0.697 |
| Hippocampal-avoidance PCI | Yes (vs. No) | 1.76 | 0.71 | 4.39 | 0.224 | 2.87 | 0.86 | 9.58 | 0.087 |
RT radiotherapy, 3D-CRT 3-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, CR complete response, PR partial response, SD stable disease, PCI prophylactic cranial irradiation, HR hazard ratio, mo months.